UPDATE 2-AstraZeneca could pay Daiichi Sankyo up to $6.9 bln in cancer drug deal [Reuters]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Reuters
AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal TOKYO (Reuters) - AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi’s cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner. The news sent Daiichi’s shares soaring 16 percent, its daily limit, to a record in morning Tokyo trading on Friday. Daiichi’s shares have climbed 45 percent this year as investor expectations for the drug rise. Under the deal, AstraZeneca will make an upfront payment of $1.35 billion to Daiichi. The two companies will share development and commercialization costs for the drug worldwide, with Daiichi retaining exclusive rights in Japan. Daiichi is the latest Japanese drugmaker to strike such a deal to gain access to a bigger overseas player’s R&D and sales clout. The deal is also a big bet on Japanese research by AstraZeneca Chief Executive Pascal Soriot, who is seeing results in his ef
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics [Yahoo! Finance]Yahoo! Finance
- Has AstraZeneca's Strong 30% Rally Left Further Upside in 2025? [Yahoo! Finance]Yahoo! Finance
- Massive U.S. drug spending gives Trump trade leverage [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASHBusiness Wire
- Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 12/4/25 - Form 6-K
- 12/1/25 - Form 6-K
- 12/1/25 - Form 6-K
- AZN's page on the SEC website